Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down – Time to Sell?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $18.84, but opened at $18.07. Daiichi Sankyo shares last traded at $18.20, with a volume of 1,913 shares changing hands.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on DSNKY shares. Zacks Research upgraded shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research report on Monday. Jefferies Financial Group cut shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. Two analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has an average rating of “Hold”.

Daiichi Sankyo Price Performance

The firm has a 50 day moving average of $17.67 and a 200 day moving average of $17.27. The firm has a market cap of $35.39 billion, a price-to-earnings ratio of 22.09, a PEG ratio of 2.61 and a beta of -0.11. The company has a quick ratio of 1.96, a current ratio of 2.92 and a debt-to-equity ratio of 0.29.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its quarterly earnings results on Friday, July 31st. The company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. As a group, sell-side analysts predict that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.97 earnings per share for the current year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its primary areas of activity include oncology, cardiovascular disease, and other specialty therapeutic fields, with an emphasis on innovative treatments and technologies.

The company is particularly known for its antibody-drug conjugate (ADC) platform, which is designed to deliver potent cancer medicines directly to tumor cells. Daiichi Sankyo’s oncology portfolio includes Enhertu (trastuzumab deruxtecan), developed in collaboration with AstraZeneca, as well as other marketed and investigational ADC therapies.